All In Biotech

Drug Trial Radar · NCT07216235

Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants With Primary Biliary Cholangitis (PBC)

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 386 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

386

Planned (sponsor's estimate)

Start

Mar 24, 2026

Primary completion

Nov 2032

Study completion Nov 2032

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Oct 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Long-Term Study to Evaluate the Safety and Efficacy in Participants with Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (EPICS-V)

Conditions

  • Primary Biliary Cholangitis

Interventions

  • Saroglitazar magnesium 1 mgDrug

    Saroglitazar magnesium 1 mg once daily, orally each morning before breakfast

  • PlaceboDrug

    Matching Placebo once daily, orally each morning before breakfast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of saroglitazar magnesium compared to placebo, based on time to the first occurrence of the defined clinical outcome events in participants with PBC.Time frame: baseline to 48 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Zydus US104

    Marietta, Georgia · Recruiting

  • Zydus US101

    Indianapolis, Indiana · Recruiting

  • Zydus US105

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.